Phytopharmaceuticals, derived from medicinal plants, have demonstrated significant therapeutic potential across numerous disease states; however, their clinical utility is often compromised by poor aqueous solubility, limited membrane permeability, rapid hepatic metabolism, and low systemic bioavailability. Conventional delivery approaches fail to address these pharmacokinetic limitations, resulting in suboptimal therapeutic outcomes and necessitating higher doses that may increase toxicity risks. Nanotechnology-based delivery systems have emerged as transformative platforms to overcome these challenges by encapsulating bioactive phytochemicals within nanocarriers such as nanoparticles, liposomes, nanoemulsions, polymeric carriers, and dendrimers. This review comprehensively examines the mechanistic basis by which these nanosystems enhance solubility, protect labile compounds from degradation, facilitate cellular uptake, enable controlled release kinetics, and achieve targeted delivery to specific tissues and cellular compartments. Preclinical studies across various animal models have consistently demonstrated superior pharmacokinetic profiles, enhanced bioavailability, prolonged circulation times, and improved therapeutic efficacy compared to free phytochemicals. Emerging clinical evidence further supports the translational potential of these nanoformulations in human populations. Critical considerations regarding biocompatibility, toxicity profiles, scalability of manufacturing processes, and regulatory frameworks are discussed in detail. Finally, future perspectives on personalized phytopharmaceutical nanotherapy, integration with precision medicine paradigms, and innovative formulation strategies are presented, highlighting the promise of nanotechnology to revolutionize the delivery and clinical application of plant-derived therapeutics in modern healthcare systems.